Cabergoline in the Management of Nonfunctioning Pituitary Adenoma
Status:
ENROLLING_BY_INVITATION
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if Cabergoline (Dostinex), a dopamine agonist which has been widely used to treat hyperprolactinemia, prolactinoma for many years, works to treat nonfunctioning pituitary adenoma (NFPA) in adults. The main questions it aims to answer are:
Does cabergoline reduce the size of NFPA effectively when used as primary therapy?
Participants will:
Be 1:1 randomized into two groups. Either to take cabergoline or none for 48 weeks, Visit the clinic every 12 weeks for checkups and tests, Undergo scheduled imaging studies, Magnetic Resonance Imaging (MRI) to measure the change of tumor size.
Phase:
PHASE4
Details
Lead Sponsor:
National Taiwan University Hospital
Collaborators:
National Taiwan University National Taiwan University Hospital Beihu Branch National Taiwan University Hospital Hsin-Chu Branch National Taiwan University Hospital, Yun-Lin Branch